AbbVie Says Imbruvica Didn't Meet Endpoints in Pancreatic Cancer Study
19 January 2019 - 9:22AM
Dow Jones News
By Stephen Nakrosis
AbbVie Inc. (ABBV) on Friday said the results of a Phase 3 study
of Imbruvica (ibrutinib) in metastatic pancreatic cancer didn't
meet its primary endpoint of improving progression-free survival or
overall survival benefit among the study population.
"We continue to evaluate the potential of Imbruvica as a cancer
treatment alone or in combination for a variety of cancer types,"
said Danelle James, M.D., M.A.S., the head of clinical science at
Pharmacyclics LLC, an AbbVie company. "We are passionately
advancing our robust ibrutinib scientific development program to
continue to advance cancer standards of care, particularly in areas
that have unmet medical need."
The trial evaluated ibrutinib in combination with certain
chemotherapy agents versus a placebo with the chemotherapy agents.
AbbVie said the study didn't show statistically significant
progression-free or overall survival benefit with ibrutinib in
combination compared with the placebo combination.
Imbruvica has been available in the U.S. since 2013 and is
FDA-approved for use with certain blood cancers and in chronic
graft-versus-host-disease, AbbVie said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 18, 2019 17:07 ET (22:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.